Relay Therapeutics, Inc. (RLAY): Submission of Matters to a Vote of Security Holders
Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001812364 --12-31 false 0001812364 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
How this was made
The 30-second read
Why it matters
The key new information is the approved increase in authorized common stock, which expands the company’s ability to issue shares without further charter changes.
Market read
This is a corporate governance/capital-structure update that can affect dilution expectations, but it does not disclose any immediate issuance or financing terms.
What to watch
Traders should check whether the company simultaneously disclosed any planned financing, ATM, or equity incentive grants elsewhere; this 8-K alone doesn’t specify issuance timing or size.
Background
The 8-K reports the outcomes of Relay Therapeutics’ annual meeting proposals, including a charter amendment to raise authorized shares.
Ticker impact
Relay Therapeutics increased its authorized common shares from 300M to 450M, approved by stockholders at its June 9 annual meeting.
Likely modest negative-to-neutral bias if traders view it as capacity for dilution; otherwise limited immediate effect absent a priced financing.
The filing discloses a corporate charter change (authorized share count) and voting results, but no accompanying financing terms or issuance size are provided.
Market effects
For small-cap biotech, authorized-share increases can signal readiness for future capital needs, affecting peer sentiment around financing risk.
None specific beyond US small-cap biotech tape.
Limited; corporate governance item with no cross-border operational change disclosed.
Counterpoint
The authorization increase may be administrative to support planned equity incentives or routine corporate actions, not necessarily imminent dilution.
Key entities
- issuerRelay Therapeutics, Inc.
Company that filed the 8-K and received stockholder approval to increase authorized common shares.
- auditorErnst & Young LLP
Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
